Policy
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The federal anti-kickback statute prevents pharmaceutical companies from providing financial coverage of Medicare copay payments that would encourage patients to purchase a company’s medication.
Most of the luxuries that we enjoy are the result of patented developments, especially in the field of biotechnology. Every time we take a medication, enjoy a food or beverage, or undergo a surgical procedure, we benefit from advances in biotechnology that might not have been available for public use without patents.
The makers of blood pressure medications can face estimated 2,000 lawsuits over the alleged carcinogen-tainted medications. Check here how much they cost.
The U.S. Department of Justice (DOJ) is reviewing a government patent for HIV, according to a retired Centers for Disease Control and Prevention (CDC) scientist.
The employees were terminated over allegations of industrial espionage on behalf of the Chinese government. MD Anderson ought to quell concerns of racial profiling following the firings.
Singapore scientists are developing a single test that can detect and differentiate multiple mosquito-borne viruses and their types
Scientists from the Agency for Science, Technology and Research’s (A*STAR), Genome Institute of Singapore (GIS), together with scientists from Duke-NUS Medical School and A*STAR’s Bioinformatics Institute (BII), have mapped out the structures of four dengue and four Zika viruses.
Biom’up announced that the U.S. Food and Drug Administration approved the IDE application for HEMOSNOW, a hemostatic dry powder made from porcine collagen and bovine-derived chondroitin sulfate developed by the Company for managing minimal and mild levels of bleeding during surgical procedures.
Accenture recently published a new report, “New Science: Biopharma’s New Growth Machine.” In it, the report attempts to evaluate the last 20 years of trends in biopharma and use that data to develop projections for the future of the industry.
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.